BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 17931655)

  • 1. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
    Aasum E; Khalid AM; Gudbrandsen OA; How OJ; Berge RK; Larsen TS
    J Mol Cell Cardiol; 2008 Jan; 44(1):201-9. PubMed ID: 17931655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.
    Ferreira AV; Parreira GG; Porto LC; Mario EG; Delpuerto HL; Martins AS; Botion LM
    Life Sci; 2008 Apr; 82(15-16):876-83. PubMed ID: 18374364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice.
    Aasum E; Cooper M; Severson DL; Larsen TS
    Can J Physiol Pharmacol; 2005 Feb; 83(2):183-90. PubMed ID: 15791292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of conjugated linoleic acid on liver composition and fatty acid oxidation are isomer-dependent in hamster.
    Macarulla MT; Fernández-Quintela A; Zabala A; Navarro V; Echevarría E; Churruca I; Rodríguez VM; Portillo MP
    Nutrition; 2005 Apr; 21(4):512-9. PubMed ID: 15811773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse.
    Brix AE; Elgavish A; Nagy TR; Gower BA; Rhead WJ; Wood PA
    Mol Genet Metab; 2002 Mar; 75(3):219-26. PubMed ID: 11914033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
    Brigadeau F; Gelé P; Wibaux M; Marquié C; Martin-Nizard F; Torpier G; Fruchart JC; Staels B; Duriez P; Lacroix D
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):408-15. PubMed ID: 17577106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
    Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in liver PPARalpha mRNA expression in response to two levels of high-safflower-oil diets correlate with changes in adiposity and serum leptin in rats and mice.
    Hsu SC; Huang CJ
    J Nutr Biochem; 2007 Feb; 18(2):86-96. PubMed ID: 16713235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats.
    Ji H; Outterbridge LV; Friedman MI
    Metabolism; 2005 Apr; 54(4):421-9. PubMed ID: 15798946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
    Berthou L; Duverger N; Emmanuel F; Langouët S; Auwerx J; Guillouzo A; Fruchart JC; Rubin E; Denèfle P; Staels B; Branellec D
    J Clin Invest; 1996 Jun; 97(11):2408-16. PubMed ID: 8647932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists.
    Yamazaki K; Kuromitsu J; Tanaka I
    Biochem Biophys Res Commun; 2002 Jan; 290(3):1114-22. PubMed ID: 11798191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
    Labinskyy V; Bellomo M; Chandler MP; Young ME; Lionetti V; Qanud K; Bigazzi F; Sampietro T; Stanley WC; Recchia FA
    J Pharmacol Exp Ther; 2007 Apr; 321(1):165-71. PubMed ID: 17215446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen.
    Jeong S; Yoon M
    Obesity (Silver Spring); 2007 Jun; 15(6):1430-40. PubMed ID: 17557980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice.
    Lee MS; Kim CT; Kim Y
    Ann Nutr Metab; 2009; 54(2):151-7. PubMed ID: 19390166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level.
    Lee GY; Kim NH; Zhao ZS; Cha BS; Kim YS
    Biochem J; 2004 Mar; 378(Pt 3):983-90. PubMed ID: 14641110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
    Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
    Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of obesity and lipid disorders by herbal extracts from Morus alba, Melissa officinalis, and Artemisia capillaris in high-fat diet-induced obese mice.
    Lee J; Chae K; Ha J; Park BY; Lee HS; Jeong S; Kim MY; Yoon M
    J Ethnopharmacol; 2008 Jan; 115(2):263-70. PubMed ID: 18023310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.